Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug…
Menarini Group’s Elacestrant Granted Priority Review By The U.S. FDA For Patients With ER+/HER2- Advanced Or Metastatic Breast Cancer
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast
Short Volatility Alert: Radius Health, Inc.
On Monday, shares of Radius Health, Inc. (NASDAQ: RDUS) experienced volatile short activity. After the activity, the stock price went up +0.69% to $10.18.
The overall sentiment for RDUS has been Bullish.
4 Analysts Have This to Say About Radius Health
Analysts have provided the following ratings for Radius Health (NASDAQ:RDUS) within the last quarter:
SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $10
SVB Leerink analyst David Risinger maintains Radius Health (NASDAQ:RDUS) with a Market Perform and raises the price target from $7 to $10.
Mosaic Tumbles Around 10%, Here’s 71 Biggest Movers From Yesterday
Gainers
Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown offering.
Bone Health Focused Radius Health Goes Private In $890M Deal
Radius Health Inc (NASDAQ:RDUS) will be acquired by Gurnet Point Capital and Patient Square Capital in a transaction valued at…
The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI’s Brain Cancer Vaccine, Xenon’s Epilepsy Candidate Shows Promise
Here's a roundup of top developments in the biotech space over the last 24 hours:
63 Biggest Movers From Yesterday
Gainers
Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
Rubric Capital Management Sends Letter To Radius Health Board Of Directors
Rubric Capital Management LP ("Rubric"), an investment advisor whose funds and accounts collectively own approximately 14.62% of the common stock of Radius Health, Inc. ("Radius" or the